Doctor of Dentistry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nishith Shah

Oral & Maxillofacial Surgery Chandler, AZ Doctor of Dentistry

NPI 1114940335 CMS profile 1106961

2450 W Ray Rd, Ste 1, Chandler, AZ 85224

Open in the dashboard

General payments

$2,231

45 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nishith Shah of Chandler, AZ is reported in the CMS Open Payments database as having received $2,231 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Oral & Maxillofacial Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $509 9
2024 General $1,010 11
2023 General $184 5
2021 General $158 8
2020 General $166 6
2019 General $203 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nishith Shah
  • Oral & Maxillofacial Surgery median
  • Middle half of Oral & Maxillofacial Surgery
  • National median

In program year 2025, general payments to Nishith Shah were reported at $509. Among 792 Oral & Maxillofacial Surgery profiles paid that year, the median was $184 and the middle half received between $61 and $541.

Show as a table
Year Nishith Shah Oral & Maxillofacial Surgery median Middle half National median
2019 $203 $178 $56–$584 $163
2020 $166 $106 $38–$316 $114
2021 $158 $165 $57–$511 $132
2022 $0 $173 $63–$494 $149
2023 $184 $184 $62–$521 $160
2024 $1,010 $197 $65–$603 $164
2025 $509 $184 $61–$541 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Keystone Dental Inc. $1,309 16 payments
  2. Nobel Biocare USA $633 20 payments
  3. Stryker Corporation $92 1 payment
  4. Geistlich Pharma, North America, Inc. $67 1 payment
  5. Pacira Pharmaceuticals Incorporated $51 2 payments
  6. KLS-Martin L.P. $42 3 payments
  7. BioHorizons Implant Systems Inc. $23 1 payment
  8. Genentech USA, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,572 33 payments
  2. Entertainment $659 12 payments
Products named General payments · program years 2019–2025
  1. NOBELACTIVE Dental implant $350 11 payments
  2. NOBELPARALLEL $350 11 payments
  3. NOBELACTIVE Dental implant $266 8 payments
  4. NOBELPROCERA $166 6 payments
  5. NOBELSPEEDY $166 6 payments
  6. NOBELREPLACE $166 6 payments
  7. SMARTLOCK $92 1 payment
  8. Geistlich Bio-Gide $67 1 payment
  9. Exparel $51 2 payments
  10. BIOHORIZONS $23 1 payment
  11. Other $136 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

914

Median for Maxillofacial Surgery: 343

Drug cost

$3,591

Median for Maxillofacial Surgery: $1,437

Branded share of claims

24.7%

Median for Maxillofacial Surgery: 21.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Chlorhexidine Gluconate Generic 396 $1,413
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 199 $807
Amoxicillin Generic 227 $557
Clindamycin Hcl Generic 39 $512
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 16 $155
Cephalexin Generic 13 $97
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 11 $26
Tramadol Hcl Generic 13 $24

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 692 Part D prescribers listed as Maxillofacial Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$26,170

Medicare's payments for the services billed

Medicare patients

92

Average age 73

Services billed

204

58 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 57%
Ischemic heart disease 32%
Diabetes 25%
Depression 24%
Atrial fibrillation 18%
Chronic kidney disease 18%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Oral & Maxillofacial Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record